MOUNTAIN VIEW, Calif. - Alto Neuroscience, Inc. (NYSE: ANRO), currently trading at $3.11 and down nearly 26% over the past week, has announced the continuation of its Phase 2b clinical trial for ...

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

Before lithium became available to treat this potentially devastating illness, bipolar I sufferers experienced repeated ...

Harvard researchers have found that M. morganii may contribute to depression by producing an inflammatory molecule.

TMS services are available at the Hays Main Office of High Plains Mental Health Center, 208 E. Seventh St. For more ...

A new treatment being offered by High Plains Mental Health Center is proving to be life-changing for some people suffering ...

Cybin pushes forward with Phase 3 depression trials after posting a narrower loss, while securing a $100M funding program.

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Virtual reality meditation effectively reduces depression and anxiety symptoms while improving emotional regulation in ...

Researchers develop machine learning tools that screen for co-morbid anxiety disorders and major depressive disorder using acoustic voice signals. The team spoke to participants with and without ...

Researchers have developed an automated screening tool that can reliably diagnose mental health issues using voice analysis.